Table 9 presents TIMP-1 concentrations in blood serum obtained only from patients with advanced stages (FIGO III and IV) of ovarian cancer. Within this group, a trend of concentration changes is shown in relation to the treatment stage, i.e., before and after cytoreductive surgery as well as during and after chemotherapy. These scarce data indicate that the highest concentration occurs after the cytoreductive procedure and the lowest concentration occurs after a completed treatment [32]. This evidence concerns the gene TIMP1 and ovarian cancer.